Brent Kokubun, MD
Foot and Ankle Surgery · Pasadena, CANPI 1538691829
Payments from drug & device makers
What this record shows
This record is dominated by grants: $10,000 of the $16,184 with a category attached, or 61.8%. Arthrex accounts for 74.2% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $12,985 and has fallen 98.6% since, to $181 in 2025. Among foot and ankle surgery clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 58 payments — averaging $279.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$12K
- Paragon 28, Inc.$2K
- Smith+Nephew$1K
- Sequoia Surgical, Inc.$674
- Saxum Surgical, Inc.$181
- Stryker$181
- plus $157 from 3 others
What the payments were for
- Grants$10,00062%
- Travel & lodging$3,03119%
- Food & beverage$2,49315%
- Education$6604%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 29 | $12,007 |
| Paragon 28, Inc. | 7 | $1,501 |
| Smith+Nephew | 10 | $1,483 |
| Sequoia Surgical, Inc. | 2 | $674 |
| Saxum Surgical, Inc. | 1 | $181 |
| Stryker | 5 | $181 |
| Extremity Medical | 1 | $89 |
| Inari Medical, Inc. | 2 | $48 |
| Kowa Pharmaceuticals America, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NA$1,306
- Taylor Spatial Frame$1,306
- Product Portfolio$1,287
- Portfolio$134
How this compares
$16,184 in reported general payments places this provider in the 90th percentile of 1,126 foot and ankle surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 24 | $220 |
| Gabapentin | 34 | $213 |
| Methylprednisolone | 15 | $86 |
| Meloxicam | 32 | $55 |
| Tramadol Hcl | 12 | $33 |
Paid to pharmacies, not to this prescriber.
Other foot and ankle surgery in Pasadena
- Thomas HarrisPasadena$3M
- Eric GizaSacramento$3.6M
- Thomas ChangSanta Rosa$2M
- Michael CoughlinSan Francisco$1.6M
- Vladimir ZeetserEncino$677K
- Jason NowakRedding$526K
- Candice BradyCamarillo$462K
- Andrew HsuOrange$456K
- Eric TanLos Angeles$447K
- Joseph ParkBurbank$387K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.